Siglecs as Therapeutic Targets in Cancer
Hypersialylation is a common post-translational modification of protein and lipids found on cancer cell surfaces, which participate in cell-cell interactions and in the regulation of immune responses. Sialic acids are a family of nine-carbon α-keto acids found at the outermost ends of glycans attach...
Guardado en:
Autores principales: | Jackwee Lim, Duygu Sari-Ak, Tanaya Bagga |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a5f210a3298541d1833f0dbe28ed2b3c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular Recognition Insights of Sialic Acid Glycans by Distinct Receptors Unveiled by NMR and Molecular Modeling
por: Cátia Oliveira Soares, et al.
Publicado: (2021) -
Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity
por: Hyeree Choi, et al.
Publicado: (2021) -
Siglec-7 May Limit Natural Killer Cell–mediated Antitumor responses in Bladder Cancer Patients
por: Sulayman Benmerzoug, et al.
Publicado: (2021) -
The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response
por: Audrey Moatti, et al.
Publicado: (2021) -
Isomer-Specific Monitoring of Sialylated N-Glycans Reveals Association of α2,3-Linked Sialic Acid Epitope With Behcet’s Disease
por: Nari Seo, et al.
Publicado: (2021)